Tech Company Financing Transactions

Cybrexa Therapeutics Funding Round

Cybrexa Therapeutics, based in New Haven, scored $13.4 million in funding from Connecticut Innovations, Cycle Capital and HighCape Partners.

Transaction Overview

Announced On
6/21/2019
Transaction Type
Venture Equity
Amount
$13,400,000
Round
Series B
Proceeds Purpose
Proceeds from the financing will be used to advance Cybrexa's first clinical candidate CBX-11 (alphalex-rucaparib) into clinical development and to progress additional programs in its preclinical pipeline.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
395 Winchester Ave. 5 Science Park
New Haven, CT 06511
USA
Email Address
Not Recorded
Overview
Cybrexa is a privately funded biotechnology company dedicated to developing an entirely new class of small molecule DNA repair inhibitors (TSDs) that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale.
Profile
Cybrexa Therapeutics LinkedIn Company Profile
Social Media
Cybrexa Therapeutics Company Twitter Account
Company News
Cybrexa Therapeutics News
Facebook
Cybrexa Therapeutics on Facebook
YouTube
Cybrexa Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chairman
Kevin Didden
  Kevin Didden LinkedIn Profile  Kevin Didden Twitter Account  Kevin Didden News  Kevin Didden on Facebook
Chief Executive Officer
Per Hellsund
  Per Hellsund LinkedIn Profile  Per Hellsund Twitter Account  Per Hellsund News  Per Hellsund on Facebook
Chief Medical Officer
Arthur DeCillis
  Arthur DeCillis LinkedIn Profile  Arthur DeCillis Twitter Account  Arthur DeCillis News  Arthur DeCillis on Facebook
Chief Medical Officer
Peter Glazer
  Peter Glazer LinkedIn Profile  Peter Glazer Twitter Account  Peter Glazer News  Peter Glazer on Facebook
Chief Scientific Officer
Vishwas Paralkar
  Vishwas Paralkar LinkedIn Profile  Vishwas Paralkar Twitter Account  Vishwas Paralkar News  Vishwas Paralkar on Facebook
Co-Founder
Ranjit Bindra
  Ranjit Bindra LinkedIn Profile  Ranjit Bindra Twitter Account  Ranjit Bindra News  Ranjit Bindra on Facebook


 

 

Browse more venture capital transactions:

Prev: 6/21/2019: Engage3 venture capital transaction
Next: 6/21/2019: Rhumbix venture capital transaction

 

Share this article

 


Where The Data Comes From

We report on funding rounds that are announced publicly. VC transactions reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary